BioCentury

8:00 AM GMT, Jan 12, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

Approval watch

Approval watch

Selected products up for approval in 2009. (A) Endo (NASDAQ:ENDP) is acquiringIndevus (NASDAQ:IDEV); (B) FDA missed Sept. 26, 2008 PDUFA date; (C) For Myozyme alglucosidase produced at the 2,000 liter bioreactor scale; (D) In September 2008, NovoNordisk (CSE:NVO; NYSE:NVO) said FDA would likely need to extend the March 23, 2009 PDUFA date by a couple of months

Company Product Indication Event Milestone
Abbott (NYSE:ABT)/Takeda (Tokyo:4502) TAK-390MR Gastroesophageal reflux disease (GERD) PDUFA date

Read the full 821 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.